What types of blood cancer diseases is Selinexor mainly used to treat?

Selinexor (Selinexor) is an oral selective nuclear export inhibitor that exerts anti-tumor effects mainly by inhibiting nuclear export protein XPO1 (Exportin 1). XPO1 is overexpressed in a variety of tumor cells, preventing tumor suppressor proteins from entering the nucleus and promoting the growth and survival of cancer cells. Selinisol inhibits the proliferation of tumor cells by blocking the function of XPO1, causing tumor suppressor proteins to accumulate in the nucleus and reactivating the cell's self-apoptotic mechanism.

In the field of hematological tumors, selinesol is mainly approved for the treatment of multiple myeloma (Multiple Myeloma). It is suitable for patients with relapsed and refractory multiple myeloma whose disease has progressed after multiple previous treatments. Clinical studies have shown that seliniso combined with low-dose dexamethasone can significantly prolong progression-free survival and improve response rates in such patients, especially providing a new treatment option for patients who are resistant to traditional therapies.

In addition to multiple myeloma, selinesol is also used to treat refractory or relapsed mantle cell lymphoma (Mantle Cell Lymphoma, MCL ). MCL is an aggressive lymphoma for which traditional treatments have limited effectiveness. With its unique mechanism of action, selinesol brings new hope to these patients. In clinical trials, selinesol monotherapy or combination therapy showed considerable objective response rates and improved patients' survival prognosis.

In addition, selinesol is also undergoing clinical studies in other hematological malignancies such as acute myeloid leukemia (AML) and diffuse largeB cell lymphoma (DLBCL), showing certain anti-tumor activity. Although it has not yet been fully approved, relevant research results provide the possibility of expanding indications in the future. Overall, selinesol, as an innovative oral drug, plays an important role in the treatment of a variety of refractory hematological tumors and is particularly suitable for patient groups in need of new treatment strategies.

Reference materials:https://www.selincro.com/